DC661

DC661 is capable of deacidifying the lysosome and inhibiting autophagy significantly better than hydroxychloroquine (HCQ). DC661 induces apoptosis.

Product information

CAS Number: 1872387-43-3

Molecular Weight: 552.58

Formula: C31H39Cl2N5

Chemical Name: 7-chloro-N-[6-({6-[(7-chloroquinolin-4-yl)amino]hexyl}(methyl)amino)hexyl]quinolin-4-amine

Smiles: CN(CCCCCCNC1C=CN=C2C=C(Cl)C=CC=12)CCCCCCNC1C=CN=C2C=C(Cl)C=CC=12

InChiKey: VJKCWFZTSDXOBS-UHFFFAOYSA-N

InChi: InChI=1S/C31H39Cl2N5/c1-38(20-8-4-2-6-16-34-28-14-18-36-30-22-24(32)10-12-26(28)30)21-9-5-3-7-17-35-29-15-19-37-31-23-25(33)11-13-27(29)31/h10-15,18-19,22-23H,2-9,16-17,20-21H2,1H3,(H,34,36)(H,35,37)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Solubility (25°C). 62 mg/mL(112.2 mM). Insoluble.

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Treatment of melanoma cells with DC661 results in a more striking accumulation of the autophagic vesicle marker LC3B-II at lower concentrations compared with either Lys05 or HCQ, reflecting more pronounced accumulation of autophagic vesicles at concentrations between 0.1 and 10 μmol/L. All cells die at concentrations above 10 μmol/L for DC661 in contrast to Lys05 and HCQ. Compared with HCQ or Lys05, DC661 treatment induces a significantly more potent inhibition of autophagic flux in melanoma cells expressing the mCherry-eGFP-LC3B reporter, and significantly higher levels of free GFP in melanoma cells expressing GFP-LC3B. DC661 treatment resulted in significantly greater lysosomal deacidification compared with either HCQ or Lys05. The IC50 of DC661 in 72-hour MTT assays is 100-fold lower than that of HCQ across multiple cancer cell lines including colon and pancreas cancer cell lines. DC661 suppresses long-term clonogenic growth of melanoma cells more effectively and induces significantly more apoptosis than Lys05, HCQ, or combined BRAF and MEK inhibition in BRAF-mutant melanoma cells.

In Vivo:

Treatment with the reduced dose (3 mg/kg, i.p.) of DC661 in a HT29 xenograft results in a significant reduction in tumor volume and almost complete suppression of daily tumor growth rate compared with control mice without significantly affecting mouse weight.

Products are for research use only. Not for human use.